Macrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ... [Yahoo! Finance]
MacroGenics, Inc. (MGNX)
Last macrogenics, inc. earnings: 11/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.macrogenics.com
Company Research
Source: Yahoo! Finance
Revenue : Total revenue decreased to $58.7 million in 2023 from $151.9 million in 2022, primarily due to a decrease in collaborative and other agreements. R&D Expenses : Decreased to $166.6 million in 2023 from $207.0 million in 2022, reflecting lower manufacturing and development costs. SG&A Expenses : Decreased to $52.2 million in 2023 from $58.9 million in 2022, mainly due to reduced selling costs for MARGENZA. Net Loss : Significantly reduced to $9.1 million in 2023 from a net loss of $119.8 million in 2022. Shares Outstanding : As of December 31, 2023, there were 62,070,627 shares of common stock outstanding. Warning! GuruFocus has detected 9 Warning Signs with MGNX. On March 7, 2024, Macrogenics Inc ( NASDAQ:MGNX ) released its 8-K filing , detailing the company's financial results for the year ended December 31, 2023, and providing an update on its corporate progress. Macrogenics, a biopharmaceutical company, is at the forefront of developing antibody-based therape
Show less
Read more
Impact Snapshot
Event Time:
MGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGNX alerts
High impacting MacroGenics, Inc. news events
Weekly update
A roundup of the hottest topics
MGNX
News
- MacroGenics, Inc. (NASDAQ: MGNX) is now covered by analysts at B. Riley. They set a "buy" rating and a $25.00 price target on the stock.MarketBeat
- Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair [Yahoo! Finance]Yahoo! Finance
- We're Hopeful That MacroGenics (NASDAQ:MGNX) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- MacroGenics, Inc. (NASDAQ: MGNX) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating.MarketBeat
- MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024 [Seeking Alpha]Seeking Alpha
MGNX
Earnings
- 11/6/23 - Beat
MGNX
Sec Filings
- 4/8/24 - Form 4
- 4/8/24 - Form ARS
- 4/8/24 - Form DEFA14A
- MGNX's page on the SEC website